Source comparison
Sermorelin for Sarcopenia Research: Protocol Comparison
Aged rodents (24-month) 300 Daily (evening) 12 weeks Grip strength, lean mass +8.4% vs control +22% muscle IGF-1 Best-validated preclinical model. Dose aligns with circadian GH peak and produces significant functional outcomes without adverse metabolic effects
This comparison does not assign a generated winner or score.
- Aged rodents (24-month)
- 300
- Daily (evening)
- 12 weeks
- Grip strength, lean mass
- +8.4% vs control
- +22% muscle IGF-1
- Best-validated preclinical model. Dose aligns with circadian GH peak and produces significant functional outcomes without adverse metabolic effects
- Aged primates (>18 years)
- 16 weeks
- Lean mass, GH pulsatility
- +5.8% vs baseline
- +18% serum IGF-1
- Closest physiological analogue to human aging. Demonstrates endogenous GH preservation that exogenous GH lacks
- In vitro myotube models
- N/A
- 48-hour exposure
- mTOR activation, protein synthesis
- +14% myofibrillar protein
- Not measured
- Confirms direct IGF-1 signaling pathway but lacks systemic feedback mechanisms present in vivo
- Aged rodents (high-dose)
- 500
- Daily
- Lean mass, glucose tolerance
- +9.1% vs control
- +26% muscle IGF-1
- Marginal benefit over 300 mcg dose. Increased transient hyperglycemia (14% incidence) without proportional strength gains